Your Search Returned 30 tagged news reports
Part 2 As was discussed in Part 1 , the Supreme Court of the United States announced last Friday that it will consider the legality of so-called "reverse-payment" arrangements, or "pay-for-delay" agreements...The case has far-reaching implications
The ninth annual prize for environmentally responsible business was presented by Bulgarian Vice-Minister of Economy Julieta Hubenova . For the 2011 edition, a record of 65 competition projects by 45 companies have been tabled for the contest. The
Signs of disintegration in Europe is leaving Dishman Pharmaceuticals and Chemicals very nervous. The company's contract-research business dependent on major pharma firms in European Union is facing the pressure of festering turmoil in the continent.
Dishman Pharmaceuticals and Chemicals will have to wait for some more time to see traction from its Switzerland subsidiary. According to its chief financial officer VVS Murthy, the growth at Swiss unit, Carbogen Amcis, was flat this year and it would
Belgian plastics and chemicals company Solvay said Monday it has made an offer to buy Paris-based chemicals firm Rhodia for euro3.4 billion ($4.84 billion). Rhodia's board of directors unanimously recommended the offer to its
Solvay said Monday the two companies have signed a framework agreement over the offer and added that the combination will "accelerate the shared ambition to create a large global chemical company committed to sustainable development." The Brussels-
Compared with this, Abbott had less than 450 products in the domestic market. "There is a scarcity of assets available to gain full ownership as we did with Piramal in this market, and we acquired one of the very best. I think we did the deal in six
Before joining Ketal, he was the president and CEO of the US and Canadian operations of Solvay Pharmaceuticals (now part of Abbott Laboratories). Arbor Pharma president and CEO Ed Schutter said that they are thrilled that Downey has accepted the
Earnings.com and Capital IQ, a division of Standard & Poor's. Yesterday's downturn, which started out worse than it ended, was likely due to the top line. Sales increased 11.8% after the acquisition of Solvay Pharmaceuticals, but missed analysts'
Abbott has posted net earnings of $891m for the third quarter 2010, or $0.57 per diluted share, compared to net earnings of $1.48bn, or $0.95 per diluted share, for the comparable period in 2009. For the nine months ended 30 September 2010, Abbott